Multi-modal and 3D Imaging for Objective Evaluation of Acne

Sachin V. Patwardhan (Canfield Scientific Inc.)

Lesion counts and Investigators Global Assessment (IGA) are the primary endpoints in acne clinical studies However, they both suffer from inter- and intra-evaluator variability Characteristics of acne lesions can be captured, detected, and objectively measured using multi-modal imaging. Collectively these detected characteristics can identify both inflammatory and non-inflammatory lesions, and the measurements can be translated to a global severity score These objective measurements have been used in several clinical studies as exploratory endpoints or for verifying subject enrollment Canfield Scientific’s VISIA-CRP now combines multi-modal imaging with micron-resolution 3D facial imaging This has further improved the ability to detect, and measure, raised topography of acne lesions. VISIA-CRP and its early use in reducing variability in clinical trials, standardizing outcomes, and obtaining more insights into treatment effects will be presented.

n Sachin V. Patwardhan, Ph.D.

Dr. Sachin V. Patwardhan is the Chief Intellectual Property Officer and Senior Principal Scientist at Canfield Scientific Inc He developed a multi-spectral imaging device for early diagnosis of melanoma during his Ph.D. at New Jersey Institute of Technology (NJIT) He then helped in establishing the optical radiology lab at Washington University School of Medicine in Saint Louis while doing postdoctoral research His research there involved developing a small animal diffuse optical and fluorescence tomography system for studying disease models with targeted treatment. Since then, for the past 16 years he has focused his research on developing optical imaging techniques and image analysis algorithms for objective assessment of skin diseases and aesthetic conditions at Canfield Scientific Inc. His work is published in several jour nals, and he has 11 granted patents and counting

Category Insights and Consumer Trends

Francine Krenicki (Crown Laboratories)

In this presentation we will discuss the acne category's past, present, and future We will analyze and provide insight to where acne treatment is headed in the future and share some experiences of what works for selected brands In addition, we will dive into ingredient trends and consumer insights n Francine Krenicki

Francine Krenicki is a beauty executive with over 20 years of experience specializing in new product development, innovation, and brand strategy and has created award winning for mulas in product categories including skincare, color, personal care, haircare, and fragrance. She has dedicated her career to creating meaningful product innovation that resonates with consumers and creates consistent brand loyalty. Currently Francine is the Senior Vice President of Global Product Development for Crown Laboratories where she oversees innovation for eight skincare brands including the iconic PanOxyl Acne line as well as the top s e l l i n g p re m i u m c l i n i c a l s k i n c a re b r a n d S t r i Ve c t i n . P r i o r t o j o i n i n g C ro w n Laboratories, Francine launched the clean clinical skincare brand Skinfix

Cutibacterium Acnes, Phages, and Acne

Nathan Brown (Parallel Health)

Acne vulgaris was first attributed to Cutibacterium acnes bacteria isolated from acne lesions by Raymond Sabouraud in 1897 Bacteriophages (phages), which infect bacteria, have been used to treat bacterial infections since they were discovered in the early 20th century Phages have

(continued on Page 12) been used to treat acne almost as long In some cases, Staphylococcus phages were used, and in other cases, Cutibacterium phages were used, which reflects the long-standing debate over which bacterium “exactly” is involved in the development of acne. Currently, specific phylotypes of C. acnes are thought to be involved in acne, though it’s still debated whether C acnes has any role to play Unfortunately, Koch’s Postulates cannot be used to clarify the role of C. acnes in acne vulgaris because the bacteria are ubiquitous on healthy skin with sebaceous glands New methods such as fine-scale population genomics of C acnes isolated from hair follicles, shotgun metagenomics methods, and topically applied phages may shed light on the role of C acnes and other bacteria in the development of acne n Nathan Brown, Ph.D.

Dr Nathan Brown ear ned his Ph D in Microbiology in 2016 from Oregon State University, where he worked on bacteriophage and bacterial genomics, and used metagenomics to study bacterial ecology He did postdoctoral work on phage therapy at the University of Leicester in Leicester, UK He left academia in 2018 to develop the world’s first phage-based cosmetic product, launched in March 2020 Since 2020, he and his cofounder, Natalise Kalea Robinson, have been developing personalized phage-based cosmetics paired with an advanced skin microbiome test at Parallel Health He has over 15 years of experience working with bacteriophages in different capacities and is passionate about introducing phages to the general population as part of a better way of life

Evaluation of Microbiome Changes Related to Cleanser Use in Healthy and Acne Prone Skin

Amina Bouslimani (L’Oréal USA)

Topical acne management involves a judicially chosen treatment regimen paired with a compatible cleanser to remove dirt and excess oil without compromising protective lipid and microbiome barrier, while addressing acne-related microbiome imbalance To build knowledge on the acute and long-ter m effect of cleansers on skin properties and the microbiome in healthy and acne-prone skin, different types of cleansers were evaluated over a 28-day regimen Facial microbiome samples were collected at different intervals after cleansing and analyzed by 16S rRNA sequencing and qPCR. The effect of cleansing on sebum and skin hydration was evaluated at the same time points n Amina Bouslimani,

All cleansers had a similar and transient effect on sebum, hydration, and bacterial diversity immediately after cleansing Cleanser composition had however a differential effect on the kinetics of skin properties and microbiome recovery These results implicate the importance of future studies to support development of next generation cleansers for healthy and acne prone skin.

Currently a Senior Scientist at L’Oréal Research and Innovation, Amina establishes exter nal partnerships with academia and industry to accelerate knowledge about the skin microbiome and identify new technologies and actives for compromised skin. Amina completed her Ph.D. in Biochemistry and Biomedical Sciences at the University of Montpellier in France where she studied the penetration and intra-tumoral metabolism of chemotherapeutic drugs in clinical samples using imaging mass spectrometry techniques She completed a postdoctoral fellowship and then worked as a Project Scientist at the University of Califor nia San Diego in Professor Pieter Dorrestein’s laboratory. She developed metabolomics-based tools to analyze and visualize large-scale metabolomics data and to link skin metabolites to their associated microbes. Her research interests included studying the impact of individual lifestyles on skin metabolites and microbes, identifying molecular biomarkers of skin conditions, and forensic applications to link skin chemical signatures to molecular traces transferred to everyday objects